Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash to Debt No Debt
NAS:OSUR's Cash to Debt is ranked higher than
95% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.37 vs. NAS:OSUR: No Debt )
Ranked among companies with meaningful Cash to Debt only.
NAS:OSUR' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 14.03 Max: No Debt
Current: No Debt
Equity to Asset 0.87
NAS:OSUR's Equity to Asset is ranked higher than
91% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. NAS:OSUR: 0.87 )
Ranked among companies with meaningful Equity to Asset only.
NAS:OSUR' s Equity to Asset Range Over the Past 10 Years
Min: 0.67  Med: 0.84 Max: 0.92
Current: 0.87
0.67
0.92
Interest Coverage No Debt
NAS:OSUR's Interest Coverage is ranked higher than
94% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 39.77 vs. NAS:OSUR: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:OSUR' s Interest Coverage Range Over the Past 10 Years
Min: 13.49  Med: No Debt Max: No Debt
Current: No Debt
F-Score: 9
Z-Score: 10.91
M-Score: -2.65
WACC vs ROIC
12.65%
29.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 13.82
NAS:OSUR's Operating margin (%) is ranked higher than
74% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.89 vs. NAS:OSUR: 13.82 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:OSUR' s Operating margin (%) Range Over the Past 10 Years
Min: -18.53  Med: -7.97 Max: 13.82
Current: 13.82
-18.53
13.82
Net-margin (%) 13.70
NAS:OSUR's Net-margin (%) is ranked higher than
83% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.04 vs. NAS:OSUR: 13.70 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:OSUR' s Net-margin (%) Range Over the Past 10 Years
Min: -43.98  Med: -7.4 Max: 13.7
Current: 13.7
-43.98
13.7
ROE (%) 10.35
NAS:OSUR's ROE (%) is ranked higher than
67% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.88 vs. NAS:OSUR: 10.35 )
Ranked among companies with meaningful ROE (%) only.
NAS:OSUR' s ROE (%) Range Over the Past 10 Years
Min: -25.18  Med: -5.07 Max: 10.35
Current: 10.35
-25.18
10.35
ROA (%) 8.79
NAS:OSUR's ROA (%) is ranked higher than
78% of the 197 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.61 vs. NAS:OSUR: 8.79 )
Ranked among companies with meaningful ROA (%) only.
NAS:OSUR' s ROA (%) Range Over the Past 10 Years
Min: -20.9  Med: -4.38 Max: 8.79
Current: 8.79
-20.9
8.79
ROC (Joel Greenblatt) (%) 61.51
NAS:OSUR's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 196 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.16 vs. NAS:OSUR: 61.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:OSUR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -47.87  Med: -22.92 Max: 61.51
Current: 61.51
-47.87
61.51
Revenue Growth (3Y)(%) 7.30
NAS:OSUR's Revenue Growth (3Y)(%) is ranked higher than
61% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.20 vs. NAS:OSUR: 7.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:OSUR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -2.7  Med: 7 Max: 34.9
Current: 7.3
-2.7
34.9
» NAS:OSUR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

OSUR Guru Trades in Q4 2015

Jim Simons 1,972,903 sh (+27.57%)
Ken Fisher 862,978 sh (+21.91%)
Paul Tudor Jones 70,575 sh (+6.95%)
PRIMECAP Management 1,950,900 sh (unchged)
Chuck Royce 689,266 sh (-7.23%)
» More
Q1 2016

OSUR Guru Trades in Q1 2016

Joel Greenblatt 19,569 sh (New)
Jim Simons 2,693,603 sh (+36.53%)
Paul Tudor Jones 89,484 sh (+26.79%)
PRIMECAP Management 1,950,900 sh (unchged)
Chuck Royce 665,766 sh (-3.41%)
Ken Fisher 824,592 sh (-4.45%)
» More
Q2 2016

OSUR Guru Trades in Q2 2016

Paul Tudor Jones 111,236 sh (+24.31%)
Joel Greenblatt 23,074 sh (+17.91%)
Jim Simons 3,098,803 sh (+15.04%)
PRIMECAP Management 1,990,900 sh (+2.05%)
Ken Fisher 824,592 sh (unchged)
Chuck Royce 625,095 sh (-6.11%)
» More
Q3 2016

OSUR Guru Trades in Q3 2016

Joel Greenblatt 38,083 sh (+65.05%)
Jim Simons 3,971,503 sh (+28.16%)
PRIMECAP Management 2,015,900 sh (+1.26%)
Chuck Royce Sold Out
Ken Fisher 623,658 sh (-24.37%)
Paul Tudor Jones 53,291 sh (-52.09%)
» More
» Details

Insider Trades

Latest Guru Trades with OSUR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:NAS:MLAB, AMEX:CRHM, NAS:LMAT, NAS:STAA, NAS:CFMS, OTCPK:GMDTF, NAS:ANGO, NAS:ELGX, NAS:ENTL, NAS:ATRC, NAS:ATRS, NAS:UTMD, OTCPK:NNCSF, NAS:NVCR, AMEX:TRXC, NAS:SIEN, NAS:DSCI, NAS:BIOL, AMEX:BVX, NAS:IVTY » details
Traded in other countries:EP3.Germany,
OraSure Technologies Inc develops, manufactures, markets and sells oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies.

OraSure Technologies Inc was formed in May 5, 2000 under Delaware law solely for the purposes of combining two companies, STC Technologies, Inc. and Epitope, Inc. and changing the state of incorporation of Epitope from Oregon to Delaware. The Company is engaged in development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies, as well as other diagnostic products including immunoassays and other in vitro diagnostic tests that are used on other specimen types. It also manufactures and sells medical devices used for the removal of benign skin lesions by cryosurgery or freezing. Its diagnostic products include tests that are performed at the point of care and tests that are processed in a laboratory. These products are sold in the United States and internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. One of its diagnostic products, the OraQuick In-Home HIV Test got approved by the U.S. FDA for sale in the over-the-counter or consumer retail markets in the United States. Its in vitro diagnostic testing is the process of analyzing oral fluid, blood, urine and other bodily fluids or tissue for the presence of specific substances or markers. Through its subsidiary, DNAG, the Company manufacture and sell kits that are used to collect, stabilize, and store samples of genetic material for molecular testing in the consumer genetics, clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. The Company owns rights to trademarks and service marks that are necessary to conduct its business as currently operated. In the United States, it owns the OraSure, Intercept, OraQuick, OraQuick ADVANCE, Histofreezer, OraSure QuickFlu, Q.E.D., Oragene, ORAcollect, OMNIgene, Performagene, PrepIT, HEMAgene, and AUTO-LYTE. The competitors include medical diagnostic companies and specialized biotechnology firms, as well as pharmaceutical companies with biotechnology divisions The Company is subject to other federal and state laws targeting fraud and abuse in the healthcare industry, including false claims laws, marketing conduct laws and laws constraining the sales, marketing and other promotional activities of manufacturers of medical devices by limiting the kinds of financial arrangements, including sales programs, with physicians, hospitals, laboratories and other potential purchasers of medical devices.

Ratios

vs
industry
vs
history
P/E(ttm) 28.44
OSUR's P/E(ttm) is ranked higher than
51% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 28.20 vs. OSUR: 28.44 )
Ranked among companies with meaningful P/E(ttm) only.
OSUR' s P/E(ttm) Range Over the Past 10 Years
Min: 10.93  Med: 67.99 Max: 500.83
Current: 28.44
10.93
500.83
Forward P/E 34.84
OSUR's Forward P/E is ranked lower than
94% of the 35 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 22.22 vs. OSUR: 34.84 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 28.44
OSUR's PE(NRI) is ranked higher than
50% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.71 vs. OSUR: 28.44 )
Ranked among companies with meaningful PE(NRI) only.
OSUR' s PE(NRI) Range Over the Past 10 Years
Min: 10.96  Med: 67.71 Max: 500.83
Current: 28.44
10.96
500.83
Price/Owner Earnings (ttm) 30.67
OSUR's Price/Owner Earnings (ttm) is ranked lower than
60% of the 81 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 25.97 vs. OSUR: 30.67 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
OSUR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 12.6  Med: 49.68 Max: 5235
Current: 30.67
12.6
5235
P/B 2.70
OSUR's P/B is ranked higher than
57% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.03 vs. OSUR: 2.70 )
Ranked among companies with meaningful P/B only.
OSUR' s P/B Range Over the Past 10 Years
Min: 0.94  Med: 2.45 Max: 6.45
Current: 2.7
0.94
6.45
P/S 3.85
OSUR's P/S is ranked lower than
59% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. OSUR: 3.85 )
Ranked among companies with meaningful P/S only.
OSUR' s P/S Range Over the Past 10 Years
Min: 1.54  Med: 3.84 Max: 8.39
Current: 3.85
1.54
8.39
PFCF 25.78
OSUR's PFCF is ranked higher than
55% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.13 vs. OSUR: 25.78 )
Ranked among companies with meaningful PFCF only.
OSUR' s PFCF Range Over the Past 10 Years
Min: 11.44  Med: 70.07 Max: 418.8
Current: 25.78
11.44
418.8
POCF 19.98
OSUR's POCF is ranked lower than
61% of the 99 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 16.52 vs. OSUR: 19.98 )
Ranked among companies with meaningful POCF only.
OSUR' s POCF Range Over the Past 10 Years
Min: 9.73  Med: 34.87 Max: 2795
Current: 19.98
9.73
2795
EV-to-EBIT 20.60
OSUR's EV-to-EBIT is ranked higher than
58% of the 121 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.32 vs. OSUR: 20.60 )
Ranked among companies with meaningful EV-to-EBIT only.
OSUR' s EV-to-EBIT Range Over the Past 10 Years
Min: -760.8  Med: -6.9 Max: 630
Current: 20.6
-760.8
630
EV-to-EBITDA 15.51
OSUR's EV-to-EBITDA is ranked higher than
58% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.51 vs. OSUR: 15.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
OSUR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1516.5  Med: -5.9 Max: 326.4
Current: 15.51
-1516.5
326.4
Current Ratio 6.87
OSUR's Current Ratio is ranked higher than
89% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.44 vs. OSUR: 6.87 )
Ranked among companies with meaningful Current Ratio only.
OSUR' s Current Ratio Range Over the Past 10 Years
Min: 2.34  Med: 5.85 Max: 11.67
Current: 6.87
2.34
11.67
Quick Ratio 6.32
OSUR's Quick Ratio is ranked higher than
90% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.60 vs. OSUR: 6.32 )
Ranked among companies with meaningful Quick Ratio only.
OSUR' s Quick Ratio Range Over the Past 10 Years
Min: 1.87  Med: 5.16 Max: 11.14
Current: 6.32
1.87
11.14
Days Inventory 119.53
OSUR's Days Inventory is ranked higher than
53% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 122.94 vs. OSUR: 119.53 )
Ranked among companies with meaningful Days Inventory only.
OSUR' s Days Inventory Range Over the Past 10 Years
Min: 71.24  Med: 114.4 Max: 134.26
Current: 119.53
71.24
134.26
Days Sales Outstanding 45.15
OSUR's Days Sales Outstanding is ranked higher than
81% of the 161 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.71 vs. OSUR: 45.15 )
Ranked among companies with meaningful Days Sales Outstanding only.
OSUR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.15  Med: 59.07 Max: 76.49
Current: 45.15
45.15
76.49
Days Payable 41.30
OSUR's Days Payable is ranked lower than
59% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.76 vs. OSUR: 41.30 )
Ranked among companies with meaningful Days Payable only.
OSUR' s Days Payable Range Over the Past 10 Years
Min: 38.26  Med: 47.45 Max: 65.49
Current: 41.3
38.26
65.49

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.30
OSUR's 3-Year Average Share Buyback Ratio is ranked higher than
72% of the 126 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -3.10 vs. OSUR: -0.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
OSUR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -40.2  Med: -5.8 Max: 11
Current: -0.3
-40.2
11

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.25
OSUR's Price/Net Cash is ranked higher than
74% of the 47 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 13.18 vs. OSUR: 5.25 )
Ranked among companies with meaningful Price/Net Cash only.
OSUR' s Price/Net Cash Range Over the Past 10 Years
Min: 1.89  Med: 6.11 Max: 101.25
Current: 5.25
1.89
101.25
Price/Net Current Asset Value 3.92
OSUR's Price/Net Current Asset Value is ranked higher than
78% of the 112 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 7.73 vs. OSUR: 3.92 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OSUR' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.4  Med: 5.16 Max: 28.26
Current: 3.92
1.4
28.26
Price/Tangible Book 3.32
OSUR's Price/Tangible Book is ranked higher than
61% of the 157 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.34 vs. OSUR: 3.32 )
Ranked among companies with meaningful Price/Tangible Book only.
OSUR' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.11  Med: 4.25 Max: 19.11
Current: 3.32
1.11
19.11
Price/Projected FCF 2.56
OSUR's Price/Projected FCF is ranked lower than
59% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.88 vs. OSUR: 2.56 )
Ranked among companies with meaningful Price/Projected FCF only.
OSUR' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.15  Med: 3.46 Max: 21.2
Current: 2.56
1.15
21.2
Price/Median PS Value 1.02
OSUR's Price/Median PS Value is ranked higher than
62% of the 160 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. OSUR: 1.02 )
Ranked among companies with meaningful Price/Median PS Value only.
OSUR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.43  Med: 1.49 Max: 6.13
Current: 1.02
0.43
6.13
Price/Graham Number 2.07
OSUR's Price/Graham Number is ranked higher than
62% of the 89 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.45 vs. OSUR: 2.07 )
Ranked among companies with meaningful Price/Graham Number only.
OSUR' s Price/Graham Number Range Over the Past 10 Years
Min: 1.4  Med: 3.95 Max: 20.7
Current: 2.07
1.4
20.7
Earnings Yield (Greenblatt) (%) 4.87
OSUR's Earnings Yield (Greenblatt) (%) is ranked higher than
74% of the 195 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.10 vs. OSUR: 4.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OSUR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 2.8 Max: 6.1
Current: 4.87
0.2
6.1
Forward Rate of Return (Yacktman) (%) 47.78
OSUR's Forward Rate of Return (Yacktman) (%) is ranked higher than
98% of the 92 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.00 vs. OSUR: 47.78 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
OSUR' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -84.8  Med: 0.2 Max: 60.4
Current: 47.78
-84.8
60.4

More Statistics

Revenue (TTM) (Mil) $125.1
EPS (TTM) $ 0.30
Beta1.37
Short Percentage of Float2.52%
52-Week Range $5.09 - 9.05
Shares Outstanding (Mil)55.73

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 127 137 130
EPS ($) 0.18 0.25 0.22
EPS w/o NRI ($) 0.18 0.25 0.22
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NAS:OSUR

Headlines

Articles On GuruFocus.com
Monday Pre-Market Insights: Pluristem Therapeutics, Juno Therapeutics, OraSure Technologies, Synergy May 18 2015 
Weekly CFO Sells Highlight: OSUR, DKS, P, MGAM, EROC Jul 09 2012 
Weekly CFO Sells Highlight: OSUR, BMC, EF, HAIN, GCI, VRSK, FIO May 21 2012 
Weekly CFO Sells Highlight: KKD, OSUR, LVLT, OVTI Jul 11 2011 
OraSure Technologies Inc. Reports Operating Results (10-Q) Nov 09 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) Aug 05 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) May 06 2010 
OraSure Technologies Inc. Reports Operating Results (10-Q) Nov 05 2009 
OraSure Technologies Inc. Reports Operating Results (10-Q) Aug 06 2009 
OraSure Technologies Inc. Reports Operating Results (10-Q) May 07 2009 

More From Other Websites
OraSure Stock Sets Up For Buy Point On Hep C Contract, Helix Win Dec 01 2016
Hedge Funds Are Unsure of OraSure Technologies, Inc. (OSUR) Nov 29 2016
ORASURE TECHNOLOGIES INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Nov 29 2016
OraSure to Implement $18 Million Product Supply Contract From Foreign Government for HCV Elimination... Nov 29 2016
Helix Selects DNA Genotek’s Oragene® Collection Device and GenoFIND Fulfillment Services for... Nov 29 2016
OraSure Technologies, Inc. (Nasdaq: OSUR) to Ring The Nasdaq Stock Market Opening Bell Nov 28 2016
OraSure Technologies to Host Analyst Day Nov 21 2016
OraSure Technologies to Host Analyst Day Nov 21 2016
ORASURE TECHNOLOGIES INC Financials Nov 16 2016
ORASURE TECHNOLOGIES INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Nov 15 2016
OraSure Technologies Appoints Stephen S. Tang, Ph.D. as Chairman of the Board of Directors Nov 15 2016
OraSure Technologies Appoints Stephen S. Tang, Ph.D. as Chairman of the Board of Directors Nov 15 2016
OraSure Technologies, Inc. breached its 50 day moving average in a Bullish Manner : OSUR-US :... Nov 14 2016
OraSure Technologies to Present at the 10th Annual Canaccord Genuity Medical Technology &... Nov 09 2016
ORASURE TECHNOLOGIES INC Files SEC form 10-Q, Quarterly Report Nov 08 2016
ETF’s with exposure to OraSure Technologies, Inc. : November 8, 2016 Nov 08 2016
OraSure Technologies, Inc. :OSUR-US: Earnings Analysis: Q3, 2016 By the Numbers : November 7, 2016 Nov 07 2016
Edited Transcript of OSUR earnings conference call or presentation 2-Nov-16 9:00pm GMT Nov 02 2016
OraSure posts 3Q profit Nov 02 2016
OraSure posts 3Q profit Nov 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)